6090 On Other Exchanges
Symbol
Exchange
6090 is not on other exchanges.

human metabolome technologie (6090) Snapshot

Open
--
Previous Close
--
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
--
EPS TTM
--
Shares Outstanding
--
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for HUMAN METABOLOME TECHNOLOGIE (6090)

Related News

No related news articles were found.

human metabolome technologie (6090) Related Businessweek News

No Related Businessweek News Found

human metabolome technologie (6090) Details

Human Metabolome Technologies, Inc. engages in contract analysis, biomarker discovery, and metabolome solution sales businesses in Japan. The company provides metabolome analysis services; research and development services in pharmaceutical, medical, food, and chemical fields; and temporary staffing services. It is also involved in search and commercialization of diagnostic biomarkers in the drug development field. The company was founded in 2003 and is headquartered in Tsuruoka, Japan.

63 Employees
Last Reported Date: 06/28/16
Founded in 2003

human metabolome technologie (6090) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

human metabolome technologie (6090) Key Developments

Human Metabolome Technologies, Inc. - Special Call

Human Metabolome Technologies, Inc. - Special Call

Human Metabolome Technologies, Inc. Reports Consolidated Earnings Results for the First Quarter Ended June 2016; Provides Earnings Guidance for the Year Ending March 2017

Human Metabolome Technologies, Inc. reported consolidated earnings results for the first quarter ended June 2016. For the quarter, the company reported net sales of ¥93 million compared to ¥89 million, operating loss of ¥109 million compared to ¥113 million, ordinary loss of ¥122 million compared to ¥112 million and loss attributable to owners of parent of ¥123 million or ¥22.64 per basic share compared to ¥112 million or ¥21.06 per basic share for the last year. The company provided earnings guidance for the year ending March 2017. For the year, the company expected net sales of ¥810 million, operating loss of ¥273 million, ordinary loss of ¥276 million and loss attributable to owners of parent of ¥279 million or ¥52.48 per basic share.

Human Metabolome Technologies, Inc. to Report Q1, 2017 Results on Aug 10, 2016

Human Metabolome Technologies, Inc. announced that they will report Q1, 2017 results on Aug 10, 2016

 

The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

6090 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 6090.
View Industry Companies
 

Industry Analysis

6090

Industry Average

Valuation 6090 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 8.6x
Price/Book 4.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 7.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact HUMAN METABOLOME TECHNOLOGIE, please visit www.humanmetabolome.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.